Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 360

1.

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Kirn DH, Thorne SH.

Nat Rev Cancer. 2009 Jan;9(1):64-71. doi: 10.1038/nrc2545. Review.

PMID:
19104515
[PubMed - indexed for MEDLINE]
2.

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Breitbach CJ, Thorne SH, Bell JC, Kirn DH.

Curr Pharm Biotechnol. 2012 Jul;13(9):1768-72. Review.

PMID:
21740365
[PubMed - indexed for MEDLINE]
3.

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J, Kirn DH.

J Clin Invest. 2007 Nov;117(11):3350-8.

PMID:
17965776
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH.

PLoS Med. 2007 Dec;4(12):e353.

PMID:
18162040
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.

Yang S, Guo ZS, O'Malley ME, Yin X, Zeh HJ, Bartlett DL.

Gene Ther. 2007 Apr;14(8):638-47. Epub 2007 Feb 1.

PMID:
17268533
[PubMed - indexed for MEDLINE]
6.

Immunotherapeutic potential of oncolytic vaccinia virus.

Thorne SH.

Immunol Res. 2011 Aug;50(2-3):286-93. doi: 10.1007/s12026-011-8211-4. Review.

PMID:
21717084
[PubMed - indexed for MEDLINE]
7.

Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.

Sinkovics JG, Horvath JC.

Arch Immunol Ther Exp (Warsz). 2008 Dec;56 Suppl 1:3s-59s. doi: 10.1007/s00005-008-0047-9. Epub 2008 Dec 23. Review.

PMID:
19104757
[PubMed - indexed for MEDLINE]
8.

Regulatory aspects of oncolytic virus products.

Yamaguchi T, Uchida E.

Curr Cancer Drug Targets. 2007 Mar;7(2):203-8. Review.

PMID:
17346112
[PubMed - indexed for MEDLINE]
9.

Employing tumor hypoxia for oncolytic therapy in breast cancer.

Chun YS, Adusumilli PS, Fong Y.

J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):311-8. Review.

PMID:
16826462
[PubMed - indexed for MEDLINE]
10.

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.

Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20.

PMID:
22186794
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Cancer gene therapy with oncolytic adenoviruses.

Guse K, Hemminki A.

J BUON. 2009 Sep;14 Suppl 1:S7-15. Review.

PMID:
19785073
[PubMed - indexed for MEDLINE]
12.

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D, Hwang TH.

Mol Ther. 2006 Sep;14(3):361-70.

PMID:
16905462
[PubMed - indexed for MEDLINE]
13.

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Todo T.

Front Biosci. 2008 Jan 1;13:2060-4. Review.

PMID:
17981691
[PubMed - indexed for MEDLINE]
14.

Oncolytic virotherapy as a personalized cancer vaccine.

Li QX, Liu G, Wong-Staal F.

Int J Cancer. 2008 Aug 1;123(3):493-9. doi: 10.1002/ijc.23692. Review.

PMID:
18500742
[PubMed - indexed for MEDLINE]
15.

The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

Thorne SH, Bartlett DL, Kirn DH.

Curr Gene Ther. 2005 Aug;5(4):429-43. Review.

PMID:
16101516
[PubMed - indexed for MEDLINE]
16.

Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.

Stanford MM, McFadden G.

Expert Opin Biol Ther. 2007 Sep;7(9):1415-25. Review.

PMID:
17727330
[PubMed - indexed for MEDLINE]
17.

A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.

Thirunavukarasu P, Sathaiah M, Gorry MC, O'Malley ME, Ravindranathan R, Austin F, Thorne SH, Guo ZS, Bartlett DL.

Mol Ther. 2013 May;21(5):1024-33. doi: 10.1038/mt.2013.27. Epub 2013 Feb 26.

PMID:
23439499
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Combining oncolytic virotherapy and tumour vaccination.

Bridle BW, Hanson S, Lichty BD.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):143-8. doi: 10.1016/j.cytogfr.2010.02.009. Epub 2010 Mar 11. Review.

PMID:
20226716
[PubMed - indexed for MEDLINE]
19.

Oncolytic vaccinia virus: from bedside to benchtop and back.

Thorne SH.

Curr Opin Mol Ther. 2008 Aug;10(4):387-92.

PMID:
18683104
[PubMed - indexed for MEDLINE]
20.

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.

Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH.

Cancer Gene Ther. 2010 Feb;17(2):73-9. doi: 10.1038/cgt.2009.50. Epub 2009 Jul 24.

PMID:
19629143
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk